USANA Health Sciences Director Timothy Wood Increases Stake with Common Stock Purchase and Restricted Stock Unit Grant

Details of Director’s Common Stock Acquisition

On July 23, 2026, USANA Health Sciences Inc. director Timothy E. Wood completed the purchase of 1,632 shares of common stock, classified as a regular purchase in the SEC filing. This transaction raised Wood’s direct beneficial ownership to 12,245 shares. The filing did not disclose the purchase price for these shares.

This acquisition represents direct ownership, with Wood holding the shares in his own name rather than through any indirect entity, reflecting his personal investment in USANA’s strategic direction and performance. The filing provides transparency on insider ownership changes as of the transaction date.

Restricted Stock Unit Grant and Vesting Timeline

Alongside the stock purchase, Wood was granted 1,632 restricted stock units (RSUs) on the same date. These RSUs entitle Wood to receive one share of USANA common stock per unit upon meeting specified conditions. Post-grant, Wood’s beneficial ownership of RSUs totaled 4,895 units.

The RSUs vest in four equal tranches over nine months, with 25% vesting on each of July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027. This staggered vesting aligns Wood’s interests with USANA’s long-term performance and incentivizes continued service and value creation through these periods.

Regulatory Filing and Disclosure Timing

The Form 4 filing was submitted on July 27, 2026, three business days after the July 23 transaction. Joshua Foukas, acting as attorney-in-fact, signed the document on Wood’s behalf. This filing complies with Section 16(a) of the Securities Exchange Act of 1934, mandating timely reporting of ownership changes by directors and officers.

Timely insider transaction disclosures help investors monitor insider sentiment and trading activity, offering insights into company valuation and prospects. Wood’s role as director makes his transactions particularly relevant to shareholders tracking insider investment patterns.

Wood’s Role and Beneficial Ownership Status

Timothy E. Wood is identified as a director of USANA Health Sciences Inc. in the Form 4 filing, without officer status or ownership exceeding ten percent of outstanding shares. His director position triggers mandatory reporting of securities transactions affecting his beneficial ownership.

Directors hold fiduciary responsibilities and their trading activity often signals their confidence or concerns regarding company strategy and valuation. Wood’s simultaneous purchase of common shares and receipt of RSUs may reflect coordinated compensation and investment strategies.

Common Stock Sales During Reporting Period

The filing also reveals Wood sold 408 shares of common stock on July 23, 2026, coded as "F" for sale, at $20.92 per share. This sale partially offset his purchase, resulting in a net increase of 1,224 shares in his direct beneficial ownership during the period.

The net increase in stock holdings and the sale price provide insight into USANA’s trading levels on the transaction date. While the filing does not explain the rationale for the sale, the smaller volume sold relative to purchased shares may indicate a positive outlook on the company.

Summary of Beneficial Ownership Changes

After all transactions on July 23, 2026, Wood’s beneficial ownership included 12,245 directly held common shares and 4,895 directly held restricted stock units. These figures reflect the net effect of acquisitions and dispositions on that date and establish a baseline for future filings.

RSUs, though contingent claims rather than actual shares, are counted in beneficial ownership as they convert to shares upon vesting. The four-tranche vesting schedule means Wood’s actual shareholding will grow progressively, contingent on continued engagement with USANA. The filing documents Wood’s current equity stake and anticipated future ownership.

Insider Trading Disclosure and Market Impact

Form 4 filings are essential to the SEC’s insider trading disclosure framework, promoting market transparency and investor confidence. Wood’s transaction details were reported within four business days, reflecting regulatory emphasis on timely information dissemination.

RSU grants are common director compensation tools to retain leadership and align incentives with shareholder value. The vesting schedule encourages sustained performance. Wood’s concurrent common stock purchase may further signal insider confidence beyond compensation equity grants.

USANA Health Sciences Corporate Governance and Market Listing

USANA Health Sciences Inc., a direct selling company specializing in nutritional and personal care products, maintains a board of directors overseeing management and strategy. Director equity ownership, as demonstrated by Wood’s transactions, helps align leadership interests with shareholder outcomes.

USANA trades on the NYSE under the ticker USNA, subjecting it to extensive SEC reporting requirements. Directors of NYSE-listed firms face stringent disclosure obligations, enhancing transparency of insider trading activities. Wood’s filing exemplifies these regulatory standards.

Tax and Regulatory Aspects of Restricted Stock Units

RSUs differ from outright shares in tax and securities treatment. Before vesting, holders lack voting and dividend rights. Wood’s RSUs vest as scheduled, converting each unit to one share with full shareholder rights. The filing clarifies the contingent nature of these units.

The four-tranche vesting may correspond with USANA’s fiscal or performance periods. The filing does not specify whether vesting depends on performance metrics, continued employment, or solely time-based conditions. The vesting timeline from July 2026 to April 2027 suggests a nine-month commitment period. Investors should review additional company disclosures for full details on vesting criteria.